Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
When treating adenocarinoma of the pancreas to 75 Gy in 25 fractions, what dose constraints do you use for small bowel, large bowel, and stomach?
What are your fields? Do you treat nodes electively?
Answer from: Radiation Oncologist at Academic Institution
Planning Volumes Definition Doses by Fractionation Scheme 15-Fraction 25-Fraction Microscopic Extension PTV CTV + 5mm (CTV = GTV + 1cm + CA, SMA, +/- porta hepatis, +/- splenic hilum basins) 37.5Gy/15 45Gy/25...
Sign in or Register to read more
4382
Related Questions
In a patient with pancreatic cancer who is heterozygous for the ATM c.875C>T (Pro292Leu) mutation with functional impairment in the gene product, is there any data or recommendation to support using SBRT vs. chemo-RT?
Would you consider long course pelvic CRT after neoadjuvant chemotherapy in a patient with low lying, locally advanced rectal adenocarcinoma when you're unable to meet small bowel constraints?
Would having mucinous rectal adenocarcinoma impact your recommendation for short vs long course RT as part of a TNT regimen?
How would you manage a patient with de novo oligometastatic anal cancer with a single metastasis in the pubic bone?
Would you offer pelvic re-irradiation in the setting of locally recurrent anal cancer in the presacral region?
What treatment sequence do you follow for patients with rectal cancer who are candidates for both PROSPECT and TNT/Watch and wait?
When treating rectal cancer with TNT and induction chemotherapy first, do you repeat pelvic MRI prior to planning for chemoradiation?
Would you dose escalate neoadjuvant radiotherapy for T3 and/or N+ rectal cancer in patients who are unwilling or unable to get chemotherapy?
What's your follow up protocol for a near complete response (nCR) in rectal patients considering non-operative management (NOM)?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?